Ironwood Pharma (IRWD) AI Stock Analysis

• Market Cap: $495.70M
• Dividend Yield: N/A
• Average Volume (3M): 3.24M
• Price to Earnings (P/E): 22.8
• Beta (1Y): 0.64
• Revenue Growth: -10.42%
• EPS Growth: N/A
• Country: US
• Employees: 253
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 163,058,320
• 10 Day Avg. Volume: 2,999,244
• 30 Day Avg. Volume: 3,243,406
• PEG Ratio: <0.01
• Price to Book (P/B): -2.09
• Price to Sales (P/S): 1.85
• P/FCF Ratio: 4.30
• Enterprise Value/Market Cap: 1.77
• Enterprise Value/Revenue: 2.96
• Enterprise Value/Gross Profit: 3.27
• Enterprise Value/Ebitda: 7.18
• 1Y Price Target: $7.50
• Price Target Upside: 146.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.87
• Revenue Forecast (FY): $460.14M

• Rating: 61 Neutral
• Price Target: $3.50 ▲(15.13% Upside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

The score is primarily supported by strong cash generation and a 2025 profitability rebound, plus constructive 2026 guidance and deleveraging plans. It is held back by a strained balance sheet with negative equity and weakening revenue, and near-term technical indicators that point to soft momentum; valuation appears only moderate given these risks.

Positive Factors

Free cash flow generation

Strong and recovered free cash flow in 2025 provides durable internal funding to repay debt, fund the STARS II trial, and support commercialization. Reliable cash conversion underpins deleveraging targets and reduces reliance on external financing over the next 2–6 months.

LINZESS commercial strength

LINZESS's large patient base, high market share and sustained prescription growth create a durable, high-margin revenue core. This entrenched commercial franchise supports near-term revenue visibility, funds R&D and provides leverage against competitor entry over the medium term.

Regulatory expansion and pipeline alignment

Label expansion into pediatric IBS-C meaningfully broadens the addressable market and creates a regulatory moat for LINZESS. Combined with aproglutide's encouraging efficacy and FDA-aligned STARS II design, the company gains durable upside from both in-market growth and a potentially high-value pipeline asset.

Negative Factors

Negative equity and weak capital structure

Negative equity signals accumulated deficits and constrains financial flexibility, increasing refinancing and covenant risk. Even with lower absolute debt, the fragile capital structure makes funding large trials, settlements, or sustained price pressure more challenging without conservative cash management.

Revenue decline and net price erosion

A trend of net price erosion and declining revenue undermines durable margin expansion and cash flow sustainability. Structural payer changes and higher Medicaid mix can keep realized prices under pressure, making long-term profit and deleveraging targets harder to sustain without offsetting volume or price improvements.

Confirmatory trial adds development risk and cost

The FDA-mandated STARS II increases timeline, cost and execution risk for aproglutide approval. Enrolling a 124-patient rare-disease trial has inherent timeline uncertainty; delays or negative outcomes would materially affect projected peak sales and the company’s planned diversification of revenue.

Ironwood Pharma Business Overview & Revenue Model

Company Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Ironwood primarily makes money from LINZESS (linaclotide) through a collaboration with AbbVie in the United States. Under this arrangement, LINZESS is commercialized in the U.S. and Ironwood earns revenue largely from its share of net profits (i.e., profit-sharing) from U.S. sales, along with collaboration-related reimbursements/other income as applicable under the partnership terms. Outside the U.S., Ironwood has historically derived additional income from territory-based arrangements (where commercialization is handled by partners), which can generate revenue in the form of royalties on partner net sales and/or milestone payments when specified regulatory, launch, or sales thresholds are achieved. As a result, Ironwood’s earnings are heavily influenced by LINZESS prescription demand and net pricing dynamics in the U.S., the cost structure and profit split within the AbbVie partnership, and any royalty or milestone receipts tied to ex-U.S. partner commercialization.

Ironwood Pharma Financial Statement Overview

Summary

Earnings and profitability rebounded in 2025 with exceptionally high margins and strong free cash flow, but the balance sheet is a major constraint due to negative equity and a relatively small asset base. Revenue has been declining and results have been volatile historically, keeping the overall financial profile mid-range despite improved debt trends.

Income Statement

Profitability rebounded strongly in 2025 with net margin near ~39% versus near breakeven in 2024, while gross margins remain exceptionally high across periods. However, the revenue trajectory is weakening (down ~13% in 2025 after modest declines in 2024), and results have shown material volatility historically (including a very large loss in 2023). Overall: strong margins and improved earnings power, but inconsistent growth and choppy bottom-line history.

Balance Sheet

The balance sheet is pressured by negative equity in the most recent two years (2024–2025), which signals accumulated deficits and reduces financial flexibility. While total debt has come down meaningfully from 2023 to 2025, leverage remains a key risk given the negative equity position and comparatively small asset base. Overall: improving debt level, but weak capital structure and elevated balance-sheet risk.

Cash Flow

Cash generation is a clear strength: operating cash flow and free cash flow are both solid and closely track reported earnings, with a sharp free-cash-flow rebound in 2025. That said, cash flow has been uneven year to year (notably lower in 2024 vs. 2023), and the company’s ability to cover obligations depends on sustaining these cash flows. Overall: strong free cash flow profile with some volatility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	296.15M	351.41M	442.74M	410.60M	413.75M
Gross Profit	294.27M	343.86M	436.59M	409.18M	343.35M
EBITDA	104.65M	97.73M	197.41M	261.44M	233.74M
Net Income	24.02M	880.00K	-1.00B	175.06M	528.45M
Balance Sheet
Total Assets	396.90M	350.91M	471.07M	1.10B	1.13B
Cash, Cash Equivalents and Short-Term Investments	215.46M	88.56M	92.15M	656.20M	620.13M
Total Debt	597.80M	599.48M	715.54M	415.92M	475.80M
Total Liabilities	658.74M	652.24M	817.37M	448.14M	521.02M
Stockholders Equity	-261.83M	-301.33M	-346.30M	652.38M	605.91M
Cash Flow
Free Cash Flow	127.01M	103.41M	183.15M	273.63M	261.63M
Operating Cash Flow	127.04M	103.55M	183.43M	273.76M	261.89M
Investing Cash Flow	-34.00K	-142.00K	-1.03B	-136.00K	-265.00K
Financing Cash Flow	216.00K	-106.97M	277.16M	-237.55M	-4.55M

Ironwood Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRWD, the sentiment is Negative. The current price of 3.04 is below the 20-day moving average (MA) of 3.49, below the 50-day MA of 4.21, and above the 200-day MA of 2.36, indicating a neutral trend. The MACD of -0.28 indicates Positive momentum. The RSI at 32.29 is Neutral, neither overbought nor oversold. The STOCH value of 12.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRWD.

Ironwood Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PCRX	67 Neutral	$895.23M	163.97	0.95%	―	3.14%	―
ANIP	67 Neutral	$1.67B	14.40	15.55%	―	48.87%	―
IRWD	61 Neutral	$495.70M	22.76	-8.22%	―	-10.42%	―
COLL	57 Neutral	$1.13B	21.64	24.11%	―	26.34%	-32.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVO	46 Neutral	$884.74M	-6.38	-18.11%	―	-1.19%	5.06%

Ironwood Pharma Corporate Events

Ironwood Pharma Maintains Revolving Credit Facility to 2028

On March 10, 2026, Ironwood Pharmaceuticals notified the administrative agent under its existing revolving credit agreement that it had satisfied the liquidity conditions specified in the contract’s definition of the maturity date. As a result, the maturity date for Ironwood’s revolving credit facility remains December 31, 2028, which helps preserve the company’s access to committed capital and supports financial flexibility for its ongoing operations and strategic plans.

The most recent analyst rating on (IRWD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.

Ironwood Pharma Resolves Ferring Dispute, Amends License Terms

On December 18, 2025, Ironwood Pharmaceuticals’ subsidiary VectivBio AG amended its exclusive license agreement with Ferring International Center to revise financial and intellectual property terms, including a total payment obligation of $12.5 million—an initial $7.5 million followed by $5 million due by December 31, 2026, subject to possible acceleration—alongside new tiered royalty commitments on net sales of licensed products. Under the revised structure, VectivBio will pay Ferring a high single-digit royalty for seven years following first commercial sale of each licensed product and a reduced low single-digit royalty thereafter until relevant patent coverage expires, while the amendment also clarifies ownership and other IP rights; on the same date, VectivBio, Ironwood and Ferring entered into a settlement and release resolving all claims related to Ferring’s lawsuit in the U.S. District Court for the Eastern District of Texas, removing a legal overhang and providing clearer economic and IP terms around the licensed portfolio.

The most recent analyst rating on (IRWD) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.